MOL PHARM

MOLECULAR PHARMACOLOGY

Peripheral Benzodiazepine Receptor: Characterization in Human T-Lymphoma Jurkat Cells

Barbara Costa, Alessandra Salvetti, Leonardo Rossi, Francesca Spinetti, Annalisa Lena, Beatrice Chelli, Mariarosa Rechichi, Eleonora Da Pozzo, Vittorio Gremigni, and Claudia Martini

Department of Psychiatry, Neurobiology, Pharmacology and Biotechnology, University of Pisa, Pisa, Italy (F.S., B.C., E.D.P., C.M.); and Department of Human Morphology and Applied Biology, University of Pisa, Pisa, Italy (B.C., A.S., L.R., A.L., M.R., V.G.)

ABSTRACT

Peripheral benzodiazepine receptor (PBR) has been considered a promising drug target for cancer therapy, and several ligands have been developed for this purpose. Human T-lymphoma Jurkat cells have been considered as lacking PBR and are often used as negative control to prove the specificity of PBR ligands effects. It is surprising that we evidenced PBR protein expression in this cell line by means of Western blotting and immunocytochemistry assays using specific anti-PBR antibodies. PBR intracellular localization was evidenced in mitochondria and nuclei, as demonstrated by confocal and electron microscopy. The binding of the [^{3}H]4′-chloro derivative of diazepam [^{3}H]7-chloro-5-(4-chlorophenyl)-1,3-dihydro-1-methyl-2*H*-1,4-benzodiazepin-2-one (Ro5-4864) and the isoquinoline carboxamide derivative [^{3}H]1-(2-chlorophenyl)-*N*-methyl-*N*-(1-methyl-propyl)-3 isoquinolinecarboxamide (PK11195) evidenced a single class of binding sites with an unusual affinity constant (K_d) of 1.77 ± 0.30 and 2.20 ± 0.20 µM, respectively. The pharmacological profile of the classic ligands showed that PK11195 was the most potent inhibitor in the radioligand binding assays followed by Ro5-4864 and diazepam, whereas clonazepam, a specific ligand for the central-type receptor, showed a $K_i > 1.0 \times 10^{-4}$ M. By a combined strategy of reverse transcriptase-polymerase chain reaction and Southern blot experiments, we succeeded in isolating and cloning the full-length Jurkat PBR cDNA, called *JuPBR*. The *JuPBR* gene showed two single-nucleotide polymorphisms resulting in the two substitutions, Ala147 → threonine and His162 → arginine, of PBR amino acidic sequence. In conclusion, for the first time, we demonstrated PBR expression in Jurkat cells: the protein bound classic PBR ligands with micromolar affinity constants and presented a modified amino acidic sequence consequent to the detection of two gene polymorphisms.

The peripheral benzodiazepine receptor (PBR), originally discovered as an alternative binding site for the benzodiazepine diazepam (Valium; Hoffman-La Roche, Nutley, NJ), forms a unique class of receptors that are pharmacologically and functionally different from the central-type receptor (Gavish et al., 1999). At a subcellular level, it has been found to be primarily localized in mitochondria at the contact sites between the outer and the inner membranes, in which it seems to take part in the formation of a heteromeric receptor complex with other proteins, including the 30-kDa adenine nucleotide transporter and the 34-kDa voltage-dependent anion channel (McEnery et al., 1992). This mitochondrial multiproteic complex has been suggested to constitute the mitochondrial permeability transition (MPT) pore, whose extensive and prolonged opening can cause the dissipation of the transmembrane mitochondrial potential leading to the release of proapoptotic intermembrane proteins. So in the machinery leading to apoptosis, MPT pore modulation has been suggested as a critical event in the regulation of processes underlying cellular survival/death (Casellas et al., 2002). Numerous findings have suggested that PBR ligands, including the benzodiazepine Ro5-4864 and the isoquinoline carboxamide derivative PK11195 (Braestrup and Squires, 1977; Le Fur et al., 1983), may act as potential therapeutic

ABBREVIATIONS: PBR, peripheral benzodiazepine receptor; PK11195, 1-(2-chlorophenyl)-*N*-methyl-*N*-(1-methyl-propyl)-3-isoquinolinecarboxamide; Ro5-4864, 7-chloro-5-(4-chlorophenyl)-1,3-dihydro-1-methyl-2*H*-1,4benzodiazepin-2-one; RT-PCR, reverse transcriptase-polymerase chain reaction; MPT, mitochondrial permeability transition; DAPI, 4,6-diamidino-2-phenylindole; PCR, polymerase chain reaction; PBS, phosphate-buffered saline; DIG, digoxigenin.

agents useful in the management of a large spectrum of diseases, including cancer, through the modulation of the MPT-pore activity (Hirsch et al., 1998; Decaudin et al., 2002; Chelli et al., 2004, 2005).

The PBR full-length cDNA was originally cloned from the rat adrenal (781 bp). Since then, human, bovine, and mouse PBR cDNAs also have been cloned (Gavish et al., 1999), and their nucleotide sequences have been found to be significantly conserved. The human PBR gene promoter is known to contain Sp1-binding sites (Lin et al., 1993), which is consistent with housekeeping gene family. Indeed, ubiquitous localization of the gene product has been observed in mammalian tissues (Gavish et al., 1999), including cells from the hematopoietic system (Canat et al., 1993; Carayon et al., 1996). Moreover, it has been demonstrated that PBR is abundantly expressed in a wide variety of malignant cells, even being the hallmark of cancerogenesis in some tissues (e.g., gliomas) (Miettinen et al., 1995). PBR expression level has been also suggested to be a clinically relevant prognosis factor in cancer (Hardwick et al., 1999, 2001). Among lymphoma cell lines (Alexander et al., 1992; Canat et al., 1993) and among myeloid/lymphoid cells from patients with leukemia (Carayon et al., 1996), a wide range of PBR expression levels have been evidenced. A peculiar condition is represented by the cell line Jurkat, deriving from a patient affected by acute lymphoblastic leukemia, in which the presence of PBR mRNA and protein is still debated. Indeed, several authors have failed to detect PBR expression (Canat et al., 1993; Carayon et al., 1996; Hans et al., 2005). Nevertheless, in the Jurkat cell line, PBR-selective ligands have been demonstrated to induce the same effects observed in other PBR-expressing cells (Zisterer et al., 2000). In addition, Decaudin and coworkers (2002) have succeeded in demonstrating detectable PBR mRNA levels in the Fas-resistant Jurkat T-cell line.

Within a general project in which we demonstrated the proapoptotic effects of classic and new synthesized PBR ligands in the C6 glioma cell line (Chelli et al., 2004, 2005), we found that PBR ligands induced cell death also in Jurkat cells, used as control (unpublished data). These findings prompted us to investigate the expression and the cellular localization of PBR in this cell line. Here, we report that Jurkat cells expressed PBR with unusual affinity constants for PBR ligands. Moreover, we demonstrated that the Jurkat PBR gene contains two point mutations reported previously in other human tumoral cell lines (Hardwick et al., 1999) and in normal cells (Kurumaji et al., 2001).

Materials and Methods

Materials. The human T-lymphoma cell line Jurkat was obtained from Interlab Cell Line Collection (http://www.biotech.ist.unige.it/interlab/cldb.html). Rat C6 glioma cells were kindly gifted by Dr. Damir Janigro (Cleveland Clinic Foundation, Cleveland, OH). Cell-culture media and fetal bovine serum were from Cambrex Bio Science Walkersville, Inc. (Walkersville, MD). PBR polyclonal primary antibodies were obtained from Santa Cruz Biotechnology (Santa Cruz, CA) and Trevigen (Gaithersburg, MD). Cytochrome *c* primary antibody and rhodamine-conjugate anti-rabbit secondary antibody were purchased by Santa Cruz Biotechnology. Horseradish peroxidase-conjugated secondary antibodies, and nonfat dry milk were from Bio-Rad (Hercules, CA). Fluorescein isothiocyanate-conjugated anti-mouse secondary antibody was from Invitrogen (Carlsbad, CA).

[^{3}H]PK11195 (specific activity, 83.5 Ci/mmol) and [^{3}H]Ro5-4864 (specific activity, 83.5 Ci/mmol) were obtained from PerkinElmer Life and Analytical Sciences (Boston, MA); PK11195, Ro5-4864, diazepam, clonazepam, and DAPI were from Sigma/RBI (Natick, MA). All other reagents were from standard commercial sources.

Cell Culture and Membrane Preparations. The human T-lymphoma cell line Jurkat (T cell derived from a patient with acute lymphoblastic leukemia) was maintained in RPMI 1640 medium supplemented with 10% fetal bovine serum, 2 mM L-glutamine, 100 U/ml penicillin, and 200 μg/ml streptomycin in a humidified atmosphere of 95% air/5% CO_2 at 37°C. Nuclear membranes from Jurkat cells were prepared as described previously (Zamzami et al., 1996). Mitochondrial membranes from Jurkat cells were prepared as described previously with minor modifications (Miccoli et al., 1999). In brief, cells were collected by centrifugation at 1000g for 5 min. The cell pellet was homogenized in 20 volumes of ice-cold buffer (0.32 M sucrose, 1 mM EDTA, 10 mM Tris-HCl, pH 7.4, containing 160 μg/ml benzamidine, 200 μg/ml bacitracin, and 20 μg/ml trypsin inhibitor) by 70 strokes of a tight-fitting glass pestle in a Potter Elvehjem glass homogenizer and centrifuged at 1500g for 5 min at 4°C. Supernatant was centrifuged at 12,000g for 10 min at 4°C. The resulting mitochondria pellet, suspended in 20 volumes of 50 mM Tris-HCl, pH 7.4, buffer and homogenized by Ultraturrax, was centrifuged at 48,000g for 20 min at 4°C. Protein concentration was estimated by the method described by Lowry et al. (1951) using bovine serum albumin as standard.

Cloning and Sequencing of PBR Gene. The full-length cDNA for the PBR gene was obtained from Jurkat cells RNA by RT-PCR. Total RNA was isolated using NucleoSpin Kit reagents, according to the manufacturer's instructions. The first-strand cDNA was obtained from 1 μg of total RNA using Superscript II RNase H-reverse transcriptase (Invitrogen) and oligo(dT)15–18. Amplification of the full-length PBR cDNA was obtained with the sequence-specific primers (PBR forward, 5′-ACAGCAGCTGCAGCAGCC-3′ and PBR reverse, 5′-ACGGCCACCACATCACAAG-3′) designed on the basis of human PBR sequence (GenBank accession number BC001110) by using Advantage 2 PCR enzyme system (BD Biosciences, San Jose, CA). After initial denaturation of cDNA at 95°C for 2 min, 35 cycles of PCR reaction were performed as follows: 95°C for 50 s, 54°C for 45 s, and 72°C for 1 min. The last cycle was extended to 10 min at 72°C. Water instead of cDNA was amplified as a negative control. Some of the amplification reaction products were resolved by agarose gel electrophoresis, transferred to a nylon membrane (Hybond N+; GE Healthcare, Little Chalfont, Buckinghamshire, UK), and probed with an internal PBR-specific DIG-labeled oligonucleotide (5′-CG-GCTCCTACCTGGTCTG-3′) according to the manufacturer's instructions (Roche Applied Science, Indianapolis, IN). Chemiluminescent detection was performed with a DIG luminescent detection kit (Roche Applied Science). The remaining PBR amplification reaction product was resolved by electrophoresis, and the PCR product corresponding to the band hybridized by the internal DIG-labeled oligonucleotide was gel-purified and cloned in pGEMT-Easy vector (Promega, Madison, WI). Several clones were sequenced by automated fluorescent cycle sequencing (Applied Biosystems, Foster City, CA).

Western Blot Analysis. Jurkat and lymphocyte cell protein samples (30 μg) were separated by SDS-polyacrylamide gel electrophoresis and transferred onto nitrocellulose membranes. The membranes were blocked for several hours in 5% blotting-grade blocker nonfat dry milk and incubated overnight with a 1:1000 dilution of anti-PBR (FL-169; Santa Cruz Biotechnology, developed against the full-length PBR of human origin) or 1:1000 of anti-PBR (Trevigen, developed against an internal sequence of PBR protein consisting of amino acids 71–88) in 1% blotting-grade blocker nonfat dry milk. After several washes in Tris-buffered saline (10 mM Tris-HCl, pH 8, and 150 mM NaCl) containing 0.05% Tween 20, antibody binding was detected using anti-rabbit horseradish peroxidase-conjugated secondary antibodies (1:100,000). Cross-reactivity was detected us-

ing the SuperSignal West Dura Extended Duration Substrate (Pierce Biotechnology, Inc., Rockford, IL). Protein concentration was assayed using a Bio-Rad assay system. In some cases, the specificity of the bands recognized by the anti-PBR antibody was demonstrated using preabsorbed antibody, prepared by incubating overnight at 4°C the anti-PBR antibody (Trevigen) with a 5-fold (by weight) excess of recombinant full-length PBR protein in a small volume of phosphate-buffered saline (PBS). In parallel, the same amount of anti-PBR antibody was incubated overnight at 4°C in PBS alone.

Immunocytochemistry and Fluorescence Microscopy. Jurkat cells were collected by centrifugation, washed in PBS, and fixed with 4% paraformaldehyde at room temperature for 30 min. A thin-layer cell preparation was obtained on poly(D-lysine)-coated glass slides by using a cytospin cytocentrifuge. Cells were blocked in PBS supplemented with 0.1% Triton X-100 and 0.5% bovine serum albumin and incubated for 1 h at room temperature in blocking solution containing 1:50 anti-PBR antibody and 1:50 anti-cytochrome c antibody (both from Santa Cruz Biotechnology) for fluorescence microscopy, or with 1:200 anti-PBR antibody (Trevigen) and 20 μg/ml DAPI for confocal microscopy. After extensive washes in blocking solution, cells were incubated for 1 h at room temperature with a 1:200 dilution of fluorescein isothiocyanate-conjugated anti-mouse secondary antibody and 1:200 dilution of rhodamine-conjugated anti-rabbit secondary antibody in blocking solution for fluorescence microscopy, or with 1:200 dilution of rhodamine-conjugated anti-rabbit secondary antibody in blocking solution for confocal microscopy. Cells were washed in PBS and mounted for microscope analysis. The analysis were performed using an Axioplan (Carl Zeiss Inc., Thornwood, NJ) epifluorescence microscope and a TCS-SP laser scanning confocal microscope (Leica Microsystems, Mannheim, Germany). A confocal series was collected every 0.15 μm. Each confocal image shown here corresponded to the middle image from a 66-section series. Negative controls were performed, omitting the primary antibodies.

Immunogold Electron Microscopy. Jurkat cells were processed for electron microscopy immunocytochemistry as described previously (Trincavelli et al., 2002) using a rabbit polyclonal anti-PBR antibody (Trevigen) diluted 1:10 in PBS containing 0.1% gelatin and 0.5% bovine serum albumin. Negative controls were performed in the absence of anti-PBR antibody. Ultrathin sections were examined using a 100 SX electron microscope (JEOL, Tokyo, Japan).

Radioligand Binding Assays. For equilibrium binding parameters determination, [3H]PK11195 and [3H]Ro5-4864 were used. [3H]PK11195 (specific activity, 0.44 Ci/mmol) binding assays were conducted in a final volume of 500 μl of 50 mM Tris-HCl, pH 7.4, buffer containing membranes (50 μg of protein) and 100 nM to 10 μM concentration of [3H]PK11195. Nonspecific binding was determined in the presence of 100 μM concentration of unlabeled PK11195. Samples were incubated in triplicate for 90 min at 0°C. In parallel,

[3H]PK11195 Scatchard analyses were carried out on human lymphocyte and C6 glioma cell membranes that were prepared as described for Jurkat cells. C6 glioma cells were cultured as described by Chelli et al. (2005).

[3H]Ro5-4864 (specific activity, 0.42 Ci/mmol) binding assays were performed in a final volume of 500 μl of 118 mM NaCl, 4.8 mM KCl, 1.2 mM CaCl$_2$, 1.2 mM MgCl$_2$, and 15 mM Tris/HCl, pH 7.4 buffer containing membranes (50 μg of protein) and 100 nM to 10 μM concentration of [3H]Ro5-4864. Nonspecific binding was determined in the presence of 100 μM concentration of unlabeled Ro5-4864. Samples were incubated in triplicate for 60 min at 4°C. Incubations were stopped by centrifugation of the samples for 2 min at 13,000g. Pellets were quickly washed three times with 1 ml of ice-cold binding assay buffer. Radioactivity in the pellets was counted after the addition of 1 ml of 0.2 N NaOH and 0.19 ml of 1 N acetic acid. Bound radioactivity was measured in a scintillation counter (TopCount; PerkinElmer Life and Analytical Sciences) using scintillation liquid (65% counting efficiency). Incubation of samples was performed in safe-lock tubes (Eppendorf AG, Hamburg, Germany). In competition experiments, membranes (50 μg of protein) were incubated with 1.5 μM [3H]PK11195 or 1.5 μM [3H]Ro5-4864 in binding assay buffer and increasing concentrations of Ro5-4864, PK11195, diazepam, and clonazepam.

The equilibrium binding of [3H]PK11195 was also measured using homologous binding displacement, whose theoretical validity has been discussed elsewhere (Rovati, 1998; Bylund and Murrin, 2000). Jurkat membranes (150 μg) were incubated with a fixed concentration of labeled ligand (0.5 μM; specific activity, 1.33 Ci/mmol) and increasing concentrations of unlabeled ligand up to 100 μM. Binding equilibrium was reached after a 90-min incubation at 0°C. Samples were filtered rapidly under vacuum through GF/C glass fiber filters to separate bound and unbound ligand. After being washed four times with 3 ml of assay buffer, radioactivity trapped on the filter was measured by liquid scintillation counting. Nonspecific binding was measured in the presence of excess PK11195 (100 μM).

Data Analysis. Saturation experiments of [3H]PK11195 and [3H]Ro5-4864 were analyzed with the EBDA and the LIGAND computer programs (Biosoft-Elsevier, Cambridge, England) (Munson and Rodbard, 1980; McPherson, 1985). Single- and multiple-site models were statistically compared with determine the best fit, and differences between models were tested by comparing the residual variance using a partial F test and a significance level of $P < 0.05$. Displacement curves were analyzed and fitted using Prism software (version 3.0; GraphPad Software Inc., San Diego, CA). Derived IC$_{50}$ values obtained from displacement curves were converted to K_i values by the Cheng and Prusoff equation (Cheng and Prusoff, 1973). Values represent the means ± S.E.M. of at least three independent experiments. Saturation data were also fitted with GraphPad Prism.

Fig. 1. PBR cDNA isolation in Jurkat cells. A, Southern blot of PBR amplification products. Lane 1, Jurkat cDNA amplified with PBR-specific primers. An autoradiographic band of approximately 600 base pairs was visible. Lane 2, negative RT-PCR control. B, comparison of the deduced amino acid sequence of Jurkat PBR (*JuPBR*) with those of other human PBR protein isoforms: MCF-7, human breast cancer cell line accession number AAC31173.1; MDA-231, human breast cancer cell line (Hardwick et al., 1999); wt-PBR, mammalian gene collection program accession number. AAH01110. Asterisks indicate the amino acid substitutions.

Results

Detection of PBR Transcript in Jurkat Cells. By using a combined strategy of RT-PCR and Southern blot experiments, we succeeded for the first time in the isolation of a full-length cDNA clone, called *JuPBR*, encoding for PBR in Jurkat cells (GenBank accession number AY998017; Fig.

Fig. 2. Western blot analysis of PBR protein. A, PBR polyclonal antibody (anti-PBR) (Trevigen) recognizes two proteins of approximately 18 and 36 kDa in both Jurkat (J) and lymphocyte (L) cells. B, specificity of the immunoreactivities seen in A, examined by preabsorbing anti-PBR with the recombinant full-length PBR protein.

1A). *JuPBR* is 593 base pairs long and contains an open reading frame encoding for a 169 amino acid putative PBR protein, with an estimated molecular mass of 18 kDa. Sequence comparison indicates that *JuPBR* shares high nucleotide identity with the other previously isolated human PBR genes. However, *JuPBR* shows a point mutation at base 526, which changes alanine (ACG) to threonine (GCG), and a point mutation at base 572, which changes arginine (CGT) to histidine (CAT) (Fig. 1B). The same variations were reported in the PBR gene isolated from other human tumoral cell lines (Hardwick et al., 1999) and, with high frequency, in genomic DNA of normal cells (Kurumaji et al., 2001).

Detection and Subcellular Localization of PBR Protein in Jurkat Cells. Using commercially available PBR polyclonal antibodies, PBR protein was identified in Jurkat cells.

Western blot analysis on total proteins obtained from Jurkat and lymphocytes cells, as control, was performed. Two different commercial polyclonal anti-PBR antibodies recognized the typical 18-kDa PBR protein in both Jurkat and lymphocyte cells. In addition, a 36-kDa protein was also detected, suggesting the presence of polymers of PBR in these cells (Fig. 2A). Immunoreactivities were specific, as demonstrated by preabsorbing the anti-PBR antibody with the recombinant full-length PBR protein (Fig. 2B).

Fig. 3. Subcellular distribution of PBR protein in Jurkat cells. A, distribution of PBR as visualized by means of an anti-PBR antibody by using fluorescent microscopy. B, subcellular distribution of mitochondria as revealed by means of an anti-cytochrome *c* antibody and fluorescent microscopy. C, merged A and B demonstrate that although PBR protein is accumulated in mitochondria, a widespread signal is also observable in other subcellular compartments. Scale bar (A–C), 10 μm. D–F, confocal fluorescence images obtained from immunocytochemistry preparations. D, distribution of PBR as revealed by use of anti-PBR antibody. E, the section depicted in D, stained with the nuclear dye DAPI; F, merged D and E demonstrate the nuclear localization of JuPBR. Scale bar (D–F), 5 μm. G, electron microscope immunocytochemistry. Large clusters of gold particles (arrows) are visible on the nucleus and cytoplasm of Jurkat cells. m, mitochondrion; N, nucleus. Scale bar, 1.5 μm.

Immunocytochemistry analysis revealed that the PBR protein seemed distributed all over the cytoplasm and at a nuclear level (Fig. 3). The use of the specific mitochondrial marker anti-cytochrome c antibody (Fig. 3B) evidenced that the pattern of the subcellular distribution of mitochondria partially overlapped the pattern of PBR staining (Fig. 3C). No signal was detected in negative controls carried out in the same experimental conditions, except that no primary antibody was added. By performing immunohistochemistry using anti-PBR antibody in combination with the specific nuclear dye DAPI and subsequent confocal microscopy, nuclear localization of PBR was demonstrated (Fig. 3, D–F). Mitochondrial and nuclear PBR localization was also confirmed by immunogold electron microscopy (Fig. 3G).

[^{3}H]PK11195 Binding Characterization. As a first step, we used Jurkat cell mitochondrial membranes for radioligand binding assays using nanomolar concentrations of [^{3}H]PK11195 as described in several cellular systems (Alexander et al., 1992; Canat et al., 1993, Hardwick et al., 1999). In these conditions, no [^{3}H]PK11195-specific binding was detected. The presence of PBR protein evidenced using the specific anti-PBR antibody, as described above, prompted us to study a potentially lower [^{3}H]PK11195 binding affinity constant in this cell line. Binding at higher ligand concentrations (>100 nM) was investigated in Jurkat cell membranes using radioligand diluted with nonradioactive ligand for lowering its specific activity (Bylund and Murrin, 2000). Moreover, bound and unbound radiolabeled ligands were separated by the centrifugation procedure according to low-affinity receptor binding assays (K_d values of approximately 10^{-7} M or 10^{-6} M) (Bennett and Yamamura, 1985). The conditions necessary for the [^{3}H]PK11195 binding were initially studied to optimize yield. In mitochondrial membrane preparations, the specific binding of [^{3}H]PK11195 increased linearly with increasing protein concentrations in the range 20 to 150 μg of protein (data not shown). To study the saturability of specific [^{3}H]PK11195 binding to Jurkat mitochondrial membranes, aliquots of membrane preparations were incubated with increasing concentrations of [^{3}H]PK11195 (100 nM to 10 μM). Specific binding of [^{3}H]PK11195 was saturable, whereas nonspecific [^{3}H]PK11195 binding increased linearly (data not shown). Scatchard analysis of the saturation data yielded a straight-line plot, compatible with the existence of a single population of binding sites (F test, $P < 0.05$) (Fig. 4). In mitochondrial membranes, the K_d value for [^{3}H]PK11195 was 2.20 ± 0.20 μM, and the maximum amount of specifically bound ligand (B_{max}) was 706 ± 75 pmol/mg of protein.

The low-affinity [^{3}H]PK11195 binding site was investigated using nonradioactive saturation experiments too. Scatchard analysis of these data indicated the existence of one class of binding sites because the one-site model yielded a significantly better fit (F test, $P < 0.05$) than fitting experimental data to a two-site model. The best fit estimated of the K_d value (9.90 ± 1 μM) for this low-affinity [^{3}H]PK11195 binding site was comparable with that obtained by "hot" saturation experiments (Fig. 5).

In nuclear membranes, Scatchard analysis of [^{3}H]PK11195 saturation data evidenced a single population of binding sites with a K_d value of 1.10 ± 0.10 μM, comparable with that obtained in mitochondrial membranes. The B_{max} value (27 ± 3 pmol/mg of protein) resulted approximately 26 times lower

than that found in mitochondrial extracts, suggesting a significant lesser expression level of PBR protein in this cell compartment. Competition experiments with specific and selective PBR ligands were performed to test the pharmacological properties of binding sites for [^{3}H]PK11195 in Jurkat cell membranes. Displacement studies of [^{3}H]PK11195 specifically bound to Jurkat cell membranes were performed by incubating aliquots of membranes with [^{3}H]PK11195 and 9 to 10 different concentrations of a ligand, as described under *Materials and Methods*. Analysis of displacement data fitted using the Prism software revealed that both the selective PBR ligands PK11195 and Ro5-4864 and the specific PBR ligand diazepam displaced specific [^{3}H]PK11195 binding in a concentration-dependent manner. K_i values of ligands are shown in Table 1. The binding of radioligand was effectively displaced by PBR ligands PK11195, Ro5-4864, and diazepam at micromolar concentrations; in contrast, clonazepam, a selective ligand for the central benzodiazepine receptor, was not effective up to 10^{-4} M.

To clarify whether the unusual [^{3}H]PK11195 low-affinity binding site evidenced in Jurkat cells was also present in cells showing [^{3}H]PK11195 high affinity, we performed on human lymphocyte and C6 glioma mitochondrial membranes

Fig. 4. Saturation curve and Scatchard plot (inset) of specific [^{3}H]PK11195 binding to mitochondrial Jurkat cell membranes. Mitochondrial membranes were incubated with increasing concentrations of [^{3}H]PK11195 ranging from 100 nM to 10 μM. Nonspecific binding was measured in the presence of 100 μM PK11195. Data are from a single experiment carried out in triplicate. The K_d and B_{max} values were 2.05 μM and 662 pmol/mg of protein, respectively. Three such experiments yielded similar results.

Fig. 5. Homologous displacement of [^{3}H]PK11195 in Jurkat cell mitochondria membranes. Bound radioactivity is expressed as a percentage of specific binding in the absence of competitor. EBDA/ligand analysis indicated a single class of binding sites with an estimated K_d = 9.90 ± 1 μM. Data points represent the means (± S.E.M.) of triplicate determinations pooled from three independent experiments.

[³H]PK11195 saturation analysis. For this purpose, we used the same experimental conditions described for Jurkat cells. Data reported in Table 2 showed that [³H]PK11195 binding parameters were similar in all analyzed cells.

[³H]Ro5-4864 Binding Characterization. Radioligand binding assays, performed as described previously (Mak and Barnes, 1989), with nanomolar concentration of [³H]Ro5-4864 did not evidence specific binding of radioligands in Jurkat cell membranes. Thus we, used the above-mentioned experimental approach for extending the [³H]Ro5-4864 concentrations range. Binding assays demonstrated specific, saturable binding of [³H]Ro5-4864 to human Jurkat cell membranes. Scatchard analysis of [³H]Ro5-4864 saturation curve revealed a single class of binding sites with a dissociation constant (K_d) of 1.77 ± 0.3 μM and a maximal binding capacity (B_{max}) of 200 ± 21 pmol/mg of protein. Scatchard plots of the binding data were linear, consistent with the interpretation that a homogeneous population of binding sites was present in membranes of Jurkat cells (Fig. 6).

The pharmacological specificity of the binding of [³H[Ro5-4864 was studied in the Jurkat cell membranes using various displacing drugs. Displacement curves were obtained in the presence of 1.5 μM [³H]Ro5-4864: the estimated K_i values for each competing ligand were calculated from these data and are presented in Table 1. In Jurkat cell membrane preparations, the tritiated ligand was effectively displaced by PK11195 and Ro5-4864. Diazepam was less effective, whereas clonazepam, at the concentration of 100 μM, was able to displace 65% of [³H]Ro5-4864 binding from its binding site.

Discussion

In the present report, we demonstrate that PBR is expressed in the human T-lymphoma Jurkat cell line and that

TABLE 1

Pharmacological characterization of [³H]PK11195 and [³H]Ro5-4864 binding to Jurkat cell line membranes

Jurkat cells membranes were incubated with 1.5 μM [³H]PK11195 or [³H]Ro5-4864 and increasing drug concentrations. The IC$_{50}$ values were calculated, and the K_i inhibitory constant was derived (Cheng and Prusoff, 1973). Each value represents the mean ± S.E.M. of three experiments, each performed in triplicate.

Compound	K_i or Percentage of Inhibition	
	vs [³H]PK11195	vs [³H]Ro5-4864
	μM	
PK11195	1.90 ± 0.20	3.68 ± 0.35
Ro5-4864	32.3 ± 4.00	8.74 ± 0.79
Diazepam	79.0 ± 8.00	18.4 ± 1.90
Clonazepam	No displacement up to 10⁻⁴ M	35 ± 4% at 10⁻⁴ M

TABLE 2

[³H]PK11195 binding parameters in Jurkat cells, lymphocytes, and C6 glioma cells

Lymphocytes, Jurkat, and C6 cell membranes were incubated with increasing concentrations of [³H]PK11195 (100 nM to 10 μM; specific activity, 0.44 Ci/mmol) as described under *Materials and Methods*. Each value represents the mean ± S.E.M. of three experiments, each performed in triplicate.

Cell Type	K_d	B_{max}
	μM	pmol/mg protein
Jurkat	2.20 ± 0.20	706 ± 75
Lymphocytes	1.80 ± 0.20	726 ± 83
C6	1.98 ± 0.20	391 ± 42

Jurkat PBR protein presents benzodiazepine and isoquinoline carboxamide ligand low-affinity binding sites.

In Jurkat cells PBR expression is still debated. By using RT-PCR, no PBR transcript was shown previously by Canat et al. (1993) and Hans et al. (2005). On the contrary, some evidences have demonstrated that PBR mRNA is expressed in human Fas-resistant T-cell line Jurkat (Decaudin et al., 2002). By using a combined strategy of RT-PCR followed by Southern blot hybridization, we succeeded in the isolation and cloning of the Jurkat PBR full-length cDNA (*JuPBR*). PBR mRNA detection required a highly sensitive experimental strategy, suggesting that Jurkat cells expressed PBR mRNA at lower level than other tumoral cell lines. Compared with the human GenBank PBR sequence, *JuPBR* showed two point mutations resulting in the change of alanine to threonine (A147T) and of histidine to arginine (H162R) localized in the fifth putative transmembrane region and in the carboxyl-terminal region of the PBR, respectively. The missense variants (A147T; H162R) have been found in other tumoral cell lines, such as MDA-231 (Hardwick et al., 1999) and, with high frequency, in genomic DNA of normal cells (Kurumaji et al., 2001), suggesting that they can be the consequence of single nucleotide polymorphisms of human PBR gene. It is not known whether these mutations have any significant effect on PBR structure and function. Molecular modeling of the receptor indicates that the first residue (A147T) lies within the cholesterol entry region of the receptor. However, this mutation does not seem to alter the ability of cholesterol to move through PBR because cholesterol is incorporated into MDA-231 nuclei (Hardwick et al., 1999). The second mutation (H162R) is a neutral mutation, given that both histidine and arginine are basic amino acids, and it is unlikely to have any significant effect on PBR function.

The PBR amino acidic substitution H162R may explain why some authors have not detected protein in Jurkat cells by using the monoclonal anti-PBR 8D7 antibody (Carayon et al., 1996; Hans et al., 2005), which recognized the human PBR C-terminal region that contains His162 instead of arginine.

In our experimental conditions, PBR expression was evidenced in Jurkat cells by using two different polyclonal anti-

Fig. 6. Saturation curve and Scatchard plot (inset) of specific [³H]Ro5-4864 binding to mitochondrial Jurkat cell membranes. Mitochondrial membranes were incubated with increasing concentrations of [³H]Ro5-4864 ranging from 100 nM to 10 μM. Nonspecific binding was measured in the presence of 100 μM Ro5-4864. Data are from a single experiment carried out in triplicate. The K_d and B_{max} values were 1.05 μM and 210 pmol/mg of protein, respectively. Three such experiments yielded similar results.

PBR antibodies that specifically recognized the 18-kDa reactive band. The data obtained by Western blot showed two different bands at 18 and 36 kDa accordingly, as reported previously in other cell lines (Delavoie et al., 2003; Corsi et al., 2005). Immunolocalization experiments provide a further demonstration of the presence of PBR protein in Jurkat cells. We evidenced PBR in mitochondria in line with other studies (Gavish et al., 1999) and in nuclei, as demonstrated previously in other tumoral cell lines (Hardwick et al., 1999; Brown et al., 2000; Delavoie et al., 2003; Corsi et al., 2005).

Emerging data have indicated that different PBR subcellular localization is frequently associated with cell malignancy. In particular, in the human aggressive phenotype of breast tumor, the PBR protein is primarily expressed in and around the nucleus (Hardwick et al., 1999). A peculiar association between PBR nuclear localization and cell malignance has also been evidenced in human gliomas (Brown et al., 2000). Further studies are necessary for understanding the association of Jurkat PBR subcellular localization and cell malignancy.

Jurkat cell line membranes were used in quantitative radioligand binding assays using the specific and selective PBR radioligands [^{3}H]PK11195 and [^{3}H]Ro5-4864. According to literature data (Canat et al., 1993), no specific [^{3}H]PK11195 binding was detected using nanomolar radioligand concentrations. However, the presence of receptor protein revealed by immunoblotting, transmission electron microscopy, and confocal microscopy analysis prompted us to investigate the possibility of more low-radioligand equilibrium binding parameters.

For this aim, we covered a higher radioligand concentration range (100 nM to 10 μM) according to the general guidelines for receptor saturation experiments (Bylund and Murrin, 2000). Scatchard analysis of the saturation [^{3}H]PK11195 binding data yielded a K_d value approximately 200 times lower than affinity constants derived from saturation studies performed on membranes of human lymphocytes and other leukemia cells (Canat et al., 1993).

A comparable low-affinity [^{3}H]PK11195 K_d value was also evidenced by using nonradioactive saturation experiments.

PBR nanomolar affinity constants have been detected in leukemia cell lines such as CCRF-CEM, Raji, and K562, whereas no binding has been evidenced using up to 20 nM PBR radioligand concentration in Molt-4B, suggesting that the absence of the high-affinity PK11195 binding parameter may not be exclusive of the Jurkat cell line (Alexander et al., 1992). Using micromolar radioligand concentration in this article, we demonstrated the presence of a low-affinity PK11195 binding site in normal immune system cells like lymphocytes and in a cell line of solid tumors like C6 glioma cells, in which a high-affinity PK11195 binding site has been reported (Alexander et al., 1992; Zisterer et al., 1998). These data suggested that the low affinity of PK11195 binding sites evidenced in Jurkat cells corresponded to a second population of binding sites, usually present in other cells.

In the Jurkat cell line, competition curve data with specific and selective PBR ligands PK11195, Ro5-4864, diazepam, or the central-type receptor-specific ligand clonazepam allowed us to derive K_i values for specific PBR ligands (listed in Table 1), whereas clonazepam was not effective up to 10^{-4} M. Although the binding affinity observed for each of these ligands ranged over several orders of magnitude compared

with that estimated in human lymphocytes and in other human cell types (Parola et al., 1993), the characteristic rank order of ligand binding potency (PK11195 > Ro5-4864 > diazepam $\gg$ clonazepam) was typical of PBR.

In the Jurkat cell line, [^{3}H]Ro5-4864 did not show specific binding at radioligand nanomolar concentrations. Scatchard analysis of [^{3}H]Ro5-4864 saturation curve, performed with experimental approaches as described above for [^{3}H]PK11195 binding assay, showed the presence of a single population of low-affinity binding sites with a dissociation constant of 1.77 $\pm$ 0.3 μM. Unlike PK11195 binding properties, that usually demonstrated a high-affinity binding in tissues from many species, Ro5-4864 binding varied depending on species and tissue. In contrast to rodent PBR (K_d = 1–10 nM), binding of Ro5-4864 to PBR of most human tissues occurred only with low affinity (K_d approximately 1 μM) (Awad and Gavish, 1991), except for human lymphocytes and platelets and the human breast cancer cell line BT-20 (K_d = 8.5 nM) (Beinlich et al., 1999). In accordance with our data, in HL-60 acute promyelocytic leukemia cell membranes, a second class of benzodiazepine binding sites with lower binding affinity has been detected (K_d value of the benzodiazepine drug [^{3}H]diazepam, 28.6 μM; B_{max}, 199 pmol/mg of protein) (Ishiguro et al., 1987). In Jurkat cell membranes, competition experiments of [^{3}H]Ro5-4864 binding with various ligands displayed the typical PBR order of potency: PK11195 > Ro5-4864 > diazepam $\gg$ clonazepam.

The first conclusion we can draw is that Jurkat cells contain PBR, which presents a micromolar affinity constant for classic ligands, and these cells cannot be used as control in an assay in which high ligand concentrations are used. The hypothesis that PBR classic high-affinity binding site could be changed in Jurkat cells as result of the two amino acidic substitutions has been discarded because human breast cancer cell lines MCF-7 and MD-231, with the same missense variants (Hardwick et al., 1999), bind the isoquinoline carboxamide derivative with high-affinity ([^{3}H]PK11195 K_d values, respectively, of 2.9 (Carmel et al., 1999) and 7.8 nM (Hardwick et al., 1999). Because PBR is associated with other proteins to constitute the mitochondrial pore, it can be hypothesized that in these tumoral cell lines, a different PBR-proteins stechiometric ratio might exist, resulting in a conformational receptor change for high-affinity binding sites. The presence of the PBR low-affinity binding site can justify micromolar PBR ligand concentration required to obtain a functional effect mediated by PBR as apoptosis induction or facilitation.

References

Alexander BE, Roller E, and Klotz U (1992) Characterization of peripheral-type benzodiazepine binding sites on human lymphocytes and lymphoma cell lines and their role in cell growth. *Biochem Pharmacol* **44:**269–274.

Awad M and Gavish M (1991) Peripheral-type benzodiazepine receptors in human cerebral cortex, kidney and colon. *Life Sci* **49:**1155–1161.

Beinlich A, Strohmeier R, Kaufmann M, and Kuhl H (1999) Specific binding of benzodiazepines to human breast cancer cell lines. *Life Sci* **65:**2099–2108.

Bennett JP and Yamamura HI (1985) Neurotransmitter, hormone, or drug receptor binding methods, in *Neurotransmitter Receptor Binding,* 2nd ed (Yamamura HI ed) pp 61–89, Raven Press, Philadelphia.

Braestrup C and Squires RF (1977) Specific benzodiazepine receptors in rat brain

characterized by high-affinity (^{3}H)diazepam binding. *Proc Natl Acad Sci USA* **74:**3805–3809.

Brown RC, Degenhardt B, Kotoula M, and Papadopoulous V (2000) Location-dependent role of the human glioma cell peripheral-type benzodiazepine receptor in proliferation and steroid biosynthesis. *Cancer Lett* **156:**125–132.

Bylund DB and Murrin LC (2000) Radioligand saturation binding experiments over large concentration ranges. *Life Sci* **67:**2897–28911.

Canat X, Carayon P, Bouaboula M, Cahard D, Shire D, Roque C, Le Fur G, and Casellas P (1993) Distribution profile and properties of peripheral-type benzodi-azepine receptors on human hemopoietic cells. *Life Sci* **52:**107–118.

Carayon P, Portier M, Dussossoy D, Bord A, Petitpretre G, Canat X, Le Fur G, and Casellas P (1996) Involvement of peripheral benzodiazepine receptors in the pro-tection of hematopoietic cells against oxygen radical damage. *Blood* **87:**3170–3178.

Carmel I, Fares FA, Leschiner S, Scherubl H, Weisinger G, and Gavish M (1999) Peripheral-type benzodiazepine receptors in the regulation of proliferation of MCF-7 human breast carcinoma cell line. *Biochem Pharmacol* **58:**273–278.

Casellas P, Galiegue S, and Basile AS (2002) Peripheral benzodiazepine receptors and mitochondrial function. *Neurochem Int* **40:**475–486.

Chelli B, Lena A, Vanacore R, Pozzo ED, Costa B, Rossi L, Salvetti A, Scatena F, Ceruti S, Abbracchio MP, et al. (2004) Peripheral benzodiazepine receptor ligands: mitochondrial transmembrane potential depolarization and apoptosis induction in rat C6 glioma cells. *Biochem Pharmacol* **68:**125–134.

Chelli B, Rossi L, Da Pozzo E, Costa B, Spinetti F, Rechichi M, Salvetti A, Lena A, Simorini F, Vanacore R, et al. (2005) PIGA (N,N-di-n-butyl-5-chloro-2-(4-chlorophenyl)indol-3-ylglyoxylamide), a new mithocondrial benzodiazepine recep-tor ligand, induces apoptosis in C6 glioma cells. *Chem Biochem* **6:**1–8.

Cheng YC and Prusoff WH (1973) Relationship between the inhibition constant (Ki) and the concentration of the inhibitor which causes 50% inhibition (IC$_{50}$) of an enzymatic reaction. *Biochem Pharmacol* **22:**3099–3108.

Corsi L, Geminiani E, Avallone R, and Baraldi M (2005) Nuclear location-dependent role of peripheral benzodiazepine receptor (PBR) in hepatic tumoral cell lines proliferation. *Life Sci* **76:**2523–2533.

Decaudin D, Castedo M, Nemati F, Beurdeley-Thomas A, De Pinieux G, Caron A, Pouillart P, Wijdenes J, Rouillard D, Kroemer G, et al. (2002) Peripheral benzo-diazepine receptor ligands reverse apoptosis resistance of cancer cells in vitro and in vivo. *Cancer Res* **62:**1388–1393.

Delavoie F, Li H, Hardwick M, Robert JC, Giatzakis C, Peranzi G, Yao ZX, Maccario J, Lacapere JJ, and Papadopoulos V (2003) In vivo and in vitro peripheral-type benzodiazepine receptor polymerization: functional significance in drug ligand and cholesterol binding. *Biochemistry* **42:**4506–4519.

Gavish M, Bachman I, Shoukrun R, Katz Y, Veenman L, Weisinger G, and Weizman A (1999) Enigma of the peripheral benzodiazepine receptor. *Pharmacol Rev* **51:**629–650.

Hans G, Wislet-Gendebien S, Lallemend F, Robe P, Rogister B, Belachew S, Nguyen L, Malgrange B, Moonen G, and Rigo JM (2005) Peripheral benzodiazepine recep-tor (PBR) ligand cytotoxicity unrelated to PBR expression. *Biochem Pharmacol* **69:**819–830.

Hardwick M, Fertikh D, Culty M, Li H, Vidic B, and Papadopoulos V (1999) Periph-eral-type benzodiazepine receptor (PBR) in human breast cancer: correlation of breast cancer cell aggressive phenotype with PBR expression, nuclear localization and PBR-mediated cell proliferation and nuclear transport of cholesterol. *Cancer Res* **59:**831–842.

Hardwick M, Rone J, Han Z, Haddad B, and Papadopoulos V (2001) Peripheral-type benzodiazepine receptor levels correlate with the ability of human breast cancer MDA-MB-231 cell line to grow in SCID mice. *Int J Cancer* **94:**322–327.

Hirsch T, Decaudin D, Susin SA, Marchetti P, Larochette N, Resche-Rigon M, and Kroemer G (1998) PK11195, a ligand of the mitochondrial benzodiazepine recep-tor, facilitates the induction of apoptosis and reverses Bcl-2-mediated cytoprotec-tion. *Exp Cell Res* **241:**426–434.

Ishiguro K, Taft WC, DeLorenzo RJ, and Sartorelli AC (1987) The role of benzodi-azepine receptors in the induction of differentiation of HL-60 leukemia cells by benzodiazepines and purines. *J Cell Physiol* **131:**226–234.

Kurumaji A, Nomoto H, Yamada K, Yoshikawa T, and Toru M (2001) No association of two missense variations of the benzodiazepine receptor (peripheral) gene and mood disorders in a Japanese sample. *Am J Med Genet* **105:**172–175.

Le Fur G, Guilloux F, Rufat P, Benavides J, Uzan A, Renault C, Dubroeucq MC, and Gueremy C (1983) Peripheral benzodiazepine binding sites: effect of PK 11195, 1-(2-chlorophenyl)-*n*-methyl-(1-methylpropyl)-3 isoquinolinecarboxamide: II. In vivo studies. *Life Sci* **32:**1849–1856.

Lin D, Chang YJ, Strauss JF, and Miller WL (1993) The human peripheral benzo-diazepine receptor gene: cloning and characterization of alternative splicing in normal tissues and in a patient with congenital lipoid adrenal hyperplasia. *Genomics* **18:**643–650.

Lowry OH, Rosebrough NJ, Farr AL, and Randall RJ (1951) Protein measurement with the Folin phenol reagent. *J Biol Chem* **193:**265–275.

Mak JC and Barnes PJ (1989) Peripheral type benzodiazepine receptors in human and guinea pig lung: characterization and autodiographic mapping. *J Pharmacol Exp Ther* **252:**880–885.

McEnery MW, Snowman AM, Trifiletti RR, and Snyder SH (1992) Isolation of the mitochondrial benzodiazepine receptor: association with the voltage-dependent anion channel and the adenine nucleotide carrier. *Proc Natl Acad Sci USA* **89:**3170–3174.

McPherson GA (1985) Analysis of radioligand binding experiments. A collection of computer programs for the IBM PC. *J Pharmacol Methods* **14:**213–228.

Miccoli L, Oudard S, Beurdeley-Thomas A, Dutrillaux B, and Poupon MF (1999) Effect of 1-(2 chlorophenyl)-N-methyl-N-(1-methylpropyl)-3-isoquinoline carbox-amide (PK11195), a specific ligand of the peripheral benzodiazepine receptor, on the lipid fluidity of mitochondria in human glioma cells. *Biochem Pharmacol* **58:**715–721.

Miettinen H, Kononen J, Haapasalo H, Helen P, Sallinen P, Harjuntausta T, Helin H, and Alho H (1995) Expression of peripheral-type benzodiazepine receptor and diazepam binding inhibitor in human astrocytomas: relationship to cell prolifera-tion. *Cancer Res* **55:**2691–2695.

Munson PJ and Rodbard D (1980) Ligand: a versatile computerized approach for characterization of ligand-binding systems. *Anal Biochem* **107:**220–239.

Parola AL, Yamamura HI, and Laird HE 3rd (1993) Peripheral-type benzodiazepine receptors. *Life Sci* **52:**1329–1342.

Rovati GE (1998) Ligand-binding studies: old beliefs and new strategies. *Trends Pharmacol Sci* **19:**365–369.

Trincavelli ML, Tuscano D, Marroni M, Falleni A, Gremigni V, Ceruti S, Abbracchio MP, Jacobson KA, Cattabeni F, and Martini C (2002) A3 adenosine receptors in human astrocytoma cells: agonist-mediated desensitization, internalization and down-regulation. *Mol Pharmacol* **62:**1373–1384.

Zamzami N, Susin SA, Marchetti P, Hirsch T, Gomez-Monterrey I, Castedo M, and Kroemer G (1996) Mitochondrial control of nuclear apoptosis. *J Exp Med* **183:**1533–1544.

Zisterer DM, Campiani G, Nacci V, and Williams DC (2000) Pyrrolo-1,5-benzoxazepines induce apoptosis in HL-60, Jurkat and Hut-78 cells: a new class of apoptotic agents. *J Pharmacol Exp Ther* **293:**48–59.

Zisterer DM, Hance N, Campiani G, Garofalo A, Nacci V, and Williams DC (1998) Antiproliferative action of pyrrolobenzoxazepine derivatives in cultured cells: ab-sence of correlation with binding to the peripheral-type benzodiazepine binding site. *Biochem Pharmacol* **55:**397–403.

Address correspondence to: Dr. Martini Claudia, Department of Psychia-try, Neurobiology, Pharmacology and Biotechnology, University of Pisa, via Bonanno, 6-56126 Pisa, Italy. E-mail: cmartini@farm.unipi.it